Literature DB >> 8429114

Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin.

P M Misiak1, M A Eldon, R D Toothaker, A J Sedman.   

Abstract

Enoxacin is a quinolone antibacterial agent currently being developed for oral and intravenous treatment of bacterial infections. Ten healthy subjects received a single 400-mg intravenous dose of enoxacin alone, with 300 mg (four times daily) oral cimetidine and with 150 mg (twice daily) oral ranitidine. Serial blood and urine samples were collected over a 48-hour period. Plasma and urine enoxacin concentrations were determined using a validated high-performance liquid chromatographic method. Mean enoxacin plasma concentrations were higher after administration of enoxacin with cimetidine than those measured after enoxacin alone or enoxacin with ranitidine. Cimetidine coadministration reduced enoxacin renal clearance by 26% and systemic clearance by 20%, and resulted in a 30% increase in elimination half-life. In contrast, concurrent ranitidine therapy did not significantly alter the pharmacokinetics of intravenous enoxacin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429114     DOI: 10.1002/j.1552-4604.1993.tb03903.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  Transport of levofloxacin in the OK kidney epithelial cell line: interaction with p-aminohippurate transport.

Authors:  Y Matsuo; I Yano; Y Habu; T Katsura; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

3.  Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats.

Authors:  I Yano; T Ito; M Takano; K Inui
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

Review 4.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.

Authors:  Aditi Mulgaonkar; Jürgen Venitz; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

6.  Effect of food and gastric pH on the bioavailability of grepafloxacin.

Authors:  C Efthymiopoulos; S L Bramer; A Maroli
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

7.  Transepithelial transport of levofloxacin in the isolated perfused rat kidney.

Authors:  T Ito; I Yano; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

Review 8.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

9.  Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers.

Authors:  Yi-Fan Zhang; Xiao-Jian Dai; Yong Yang; Xiao-Yan Chen; Ting Wang; Yun-Biao Tang; Cheng-Yuan Tsai; Li-Wen Chang; Yu-Ting Chang; Da-Fang Zhong
Journal:  Drug Des Devel Ther       Date:  2016-01-20       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.